CNR1 and bone cancer: Indeed, systemic and spinal administration of CB1 (ACEA, PrNMI), CB2 (JWH015, AM1241) and mixed CB1/CB2 (WIN55,212-2) agonists were shown to exert anti-allodynic and anti-hyperalgesic effects in different models of bone cancer pain69,73–78.